NEW YORK (TheStreet) -- TheStreet'saJim Crameratalks about the breakout news ofaRegenerona and its partneraSanofia , who teamed up to createaa cholesterol drug called alirocumab that would be used with the statin class of cholesterol drugs to decrease the hard-to-reduce cholesterol levels.a Cramer says this is great news for the approximately 12 million people who are allergic to the statin class. He thinks this is a multi-billion dollar drug foraRegeneron and the company is finally breaking out. Cramer thinks this makes all sorts of sense because the drug cuts heart rate failure risk and stroke risk. Cramer thinks Renegeron is a better way to play this news thanaSanofi. Must Read:aCramer: What's Working, What's Not STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. REGN data by YCharts EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.
Click to view a price quote on REGN. Click to research the Drugs industry.
from Latest TSC Headlines http://ift.tt/1q8ucHr
No comments:
Post a Comment